A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to characterize the safety profile of ZD1839 in combination with Palliative thoracic Radiotherapy in patients with non-small cell lung cancer

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Gefitinib

Criteria

Inclusion Criteria:

• Provision of written informed consent

• Patients requiring low dose palliative thoracic irradiation to a field size of less than or equal to 150cm2

• Histologically or cytologically conformed non-small cell lung cancer

• Aged 18 or over

Exclusion Criteria:

• Previous thoracic radiotherapy

• Any condition that may pre-dispose the patient to suffer an individual drug-relaged DLT (dose limiting toxicity) event

• Known hypersensitivity to any component of study medication